Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) is a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, based in California. They just announced the completion of the final phase of construction at their 30,000-square-foot cannabis cultivation facility in Stockton, California, and their webinar offering a look at the Stockton construction and an update on pharmaceutical developments.
Juva’s CEO and Founder Doug Chloupek commented, “The successful completion of this expansion will effectively double the capacity of our Stockton cultivation facility. We are grateful for our hard-working teams that helped us successfully complete the expansion of this facility, and we are excited to see the increase in revenue it will produce.”
Cannabis and Life Sciences Company Doubles Capacity of Stockton Cultivation Facility With Completed Construction
The completion of all construction doubles the number of cannabis flower cultivation rooms from three to six rooms, without increasing costs, and also maximizes the facility’s current systems. The final phase of construction costs are about $2.6 million, whereas the total cost of construction for the facility was just about $12.5 million.
Juva had nine successful harvests in 2021 and the team is on schedule to have 33 planned harvests in 2022 with an average yield of 1.5 pounds per light, and a target of 2-2.5 pounds per light. There are currently 588 lights in the flower rooms and 196 in the vegetative room.
Juva Life Remains Focused on Pharmaceutical Cannabis Research
Chloupek continued, “Our focus as a company remains on the promising research on our two proprietary molecular compounds, JUVA-019 and JUVA-041, as we continue down our path to identify pharmacological compounds with potential to treat health effects such as inflammation in the human body.”
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry.
Additionally, Juva hosted a live Zoom webinar on March 23, 2022, which showcased the Company’s construction updates and advancements and provided an update on its cannabis and pharmaceutical operations. Those interested in viewing the webinar can view it on the Juva Life website.
